| CANCER |
DATASET |
DESCRIPTION |
TOTAL SAMPLES |
TOTAL GENES |
VERSION |
| ADRENAL |
GSE33371 |
GSE33371 - Beta-catenin status effects in human adrenocortical carcinomas (33), adenomas (22), and normal adrenal cortex (10) |
23 |
21212 |
V1 |
| ADRENAL |
GSE19776 |
GSE19776 - Adrenocortical Carcinoma Gene Expression Profiling |
22 |
21933 |
V2 |
| BLADDER |
GSE13507 |
GSE13507 - Predictive Value of Prognosis-Related Gene Expression Study in Primary Bladder Cancer |
165 |
24357 |
V1 |
| BLADDER |
GSE19915 |
GSE19915 - Subtype classification, grading, and outcome prediction of urothelial carcinomas by combined mRNA profiling and aCGH |
144 |
2506 |
V1 |
| BLADDER |
TCGA_BLCA |
TCGA BLADDER CARCINOMA DATA |
123 |
15448 |
V1 |
| BLADDER |
GSE31684 |
GSE31684 - Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer |
93 |
21702 |
V1 |
| BLADDER |
GSE48276 |
GSE48276 - Gene expression profiling of urothelial carcinoma |
73 |
20717 |
V2 |
| BONE |
GSE21257 |
GSE21257 - Genome-wide gene expression profiling on pre-chemotherapy biopsies of osteosarcoma patients |
53 |
24996 |
V1 |
| BRAIN |
TCGA_GBM |
TCGA DATA GLIOBLASTOMA MULTIFORME |
577 |
17813 |
V1 |
| BRAIN |
GSE16011 |
GSE16011 - Intrinsic Gene Expression Profiles of Gliomas are a Better Predictor of Survival than Histology |
262 |
21212 |
V1 |
| BRAIN |
TCGA_LGG |
TCGA LOWER GRADE GLIOMA DATA |
206 |
16467 |
V1 |
| BRAIN |
GSE13041_U133 |
GSE13041 - Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age |
191 |
13480 |
V1 |
| BRAIN |
GSE4412_U133A |
freij-affy-human-91666 |
83 |
13720 |
V2 |
| BRAIN |
GSE4412_U133B |
freij-affy-human-91666 |
83 |
10688 |
V2 |
| BRAIN |
GSE4271_U133B |
Molecular subclasses of high-grade glioma: prognosis, disease progression, and neurogenesis |
78 |
10688 |
V2 |
| BRAIN |
GSE7696 |
GSE7696 - Glioblastoma from a homogenous cohort of patients treated within clinical trial |
77 |
21212 |
V1 |
| BRAIN |
GSE4271_U133A |
Molecular subclasses of high-grade glioma: prognosis, disease progression, and neurogenesis |
77 |
13720 |
V2 |
| BRAIN |
GSE37418 |
GSE37418 - Novel mutations target distinct subgroups of medulloblastoma. |
75 |
21703 |
V2 |
| BRAIN |
GSE16581 |
GSE16581 - Genomic landscape of meningiomas: gene expression |
67 |
21703 |
V2 |
| BRAIN |
GSE42669 |
GSE42669 - Patient specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ (gene expression) |
55 |
21092 |
V2 |
| BRAIN |
GSE13041_U95v2 |
GSE13041 - Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. AffyU95 Samples |
49 |
9383 |
V1 |
| BRAIN |
GSE30074 |
GSE30074 - Expression data from 30 medulloblastomas |
30 |
21103 |
V2 |
| BRAIN |
GSE2817 |
GSE2817 - Wavelet modelling of microarray data provides chromosomal pattern of expression which predicts survival in gliomas |
25 |
21703 |
V2 |
| BREAST |
TCGA |
TCGA - TCGA BREAST CANCER DATA |
596 |
17813 |
V1 |
| BREAST |
GSE17705 |
GSE17705 - Endocrine Sensitivity Index Validation Dataset |
298 |
13480 |
V1 |
| BREAST |
NKI |
NKI - A gene-expression signature as a predictor of survival in breast cancer |
295 |
11475 |
V1 |
| BREAST |
GSE2034 |
GSE2034 - Breast cancer relapse free survival |
286 |
13480 |
V1 |
| BREAST |
GSE4922_U133A |
GSE4922_U133A - Genetic Reclassification of Histologic Grade Delineates New Clinical Subtypes of Breast Cancer |
249 |
13480 |
V1 |
| BREAST |
GSE4922_U133B |
GSE4922_U133B - Genetic Reclassification of Histologic Grade Delineates New Clinical Subtypes of Breast Cancer |
248 |
9856 |
V1 |
| BREAST |
GSE3494_U133B |
GSE3494_U133B - An expression signature for p53 in breast cancer predicts mutation status, transcriptional effects, and patient survival |
236 |
9856 |
V1 |
| BREAST |
GSE3494_U133A |
GSE3494_U133A - An expression signature for p53 in breast cancer predicts mutation status, transcriptional effects, and patient survival |
236 |
13480 |
V1 |
| BREAST |
GSE11121 |
GSE11121 - The humoral immune system has a key prognostic impact in node-negative breast cancer |
200 |
13480 |
V1 |
| BREAST |
GSE7390 |
GSE7390 - Strong Time Dependence of the 76-Gene Prognostic Signature |
198 |
13480 |
V1 |
| BREAST |
GSE6532_U133A |
GSE6532_U133A - Definition of clinically distinct molecular subtypes in estrogen receptor positive breast carcinomas using genomic grade |
189 |
13480 |
V1 |
| BREAST |
GSE48408 |
GSE48408 - Long non-coding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor positive primary breast cancer |
164 |
21793 |
V2 |
| BREAST |
GSE1456_U133B |
GSE1456_U133B - Gene expression of breast cancer tissue in a large population-based cohort of Swedish patients |
159 |
9856 |
V1 |
| BREAST |
GSE1456_U133A |
GSE1456_U133A - Gene expression of breast cancer tissue in a large population-based cohort of Swedish patients |
159 |
13480 |
V1 |
| BREAST |
GSE12093 |
GSE12093 - The 76-gene Signature Defines High-Risk Patients that Benefit from Adjuvant Tamoxifen Therapy |
132 |
13476 |
V1 |
| BREAST |
GSE6532_U133B |
GSE6532_U133B - Definition of clinically distinct molecular subtypes in estrogen receptor positive breast carcinomas using genomic grade |
126 |
9856 |
V1 |
| BREAST |
GSE19615 |
GSE19615 - Integrated genomic and function characterization of the 8q22 gain |
115 |
21212 |
V1 |
| BREAST |
GSE42568 |
GSE42568 - Breast Cancer Gene Expression Analysis |
104 |
21703 |
V2 |
| BREAST |
GSE2990 |
GSE2990 - Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis |
101 |
13480 |
V1 |
| BREAST |
GSE6532_U133_P2 |
GSE6532_U133_P2 - Definition of clinically distinct molecular subtypes in estrogen receptor positive breast carcinomas using genomic grade |
87 |
21212 |
V1 |
| BREAST |
GSE2603 |
GSE2603 - Subpopulations of MDA-MB-231 and Primary Breast Cancers |
82 |
13480 |
V1 |
| BREAST |
GSE9195 |
GSE9195 - Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen |
77 |
21212 |
V1 |
| BREAST |
GSE1379 |
GSE1379 - breast cancer / tamoxifen monotherapy (whole tissue tumor biopsies) |
60 |
15369 |
V1 |
| BREAST |
GSE37751 |
GSE37751 - Molecular Profiles of Human Breast Cancer and Their Association with Tumor Subtypes and Disease Prognosis (Affymetrix) |
60 |
21093 |
V2 |
| BREAST |
GSE5327 |
GSE5327 - Breast cancer relapse free survival and lung metastasis free survival |
58 |
13480 |
V1 |
| CERVICAL |
GSE44001 |
GSE44001 - Genetic profiling to predict recurrence of early cervical cancer |
300 |
20669 |
V2 |
| COLON |
GSE39582 |
GSE39582 - Gene expression Classification of Colon Cancer defines six molecular subtypes with distinct clinical, molecular and survival characteristics [Expression] |
566 |
21703 |
V2 |
| COLON |
GSE14333 |
GSE14333 - Expression data from 290 primary colorectal cancers |
187 |
21703 |
V2 |
| COLON |
GSE41258 |
GSE41258 - Expression data from colorectal cancer patients |
182 |
13720 |
V2 |
| COLON |
GSE17536 |
GSE17536 - Metastasis Gene Expression Profile Predicts Recurrence and Death in Colon Cancer Patients |
174 |
21212 |
V1 |
| COLON |
GSE24551 |
GSE24551 - Exon level expression profiling of colorectal cancer tissue samples |
160 |
14984 |
V2 |
| COLON |
GSE28722 |
GSE28722 - EMT is the dominant program in human colon cancer (Agilent) |
125 |
15218 |
V2 |
| COLON |
GSE28814 |
GSE28814 - EMT is the dominant program in human colon cancer |
122 |
15240 |
V1 |
| COLON |
TCGA_COAD |
TCGA DATA COLON ADENOCARCINOMA |
121 |
17813 |
V1 |
| COLON |
GSE30378 |
GSE30378 - Gene level expression profiling of colorectal cancer tissue samples (test sample series) |
95 |
14984 |
V2 |
| COLON |
GSE29621 |
GSE29621 - mRNA and microRNA profile in colon cancer [mRNA data] |
65 |
21703 |
V2 |
| COLON |
GSE12945 |
GSE12945 - Expression data from colorectal cancers |
62 |
13720 |
V2 |
| COLON |
GSE17537 |
GSE17537- Metastasis Gene Expression Profile Predicts Recurrence and Death in Colon Cancer Patients |
52 |
21212 |
V1 |
| COLON |
GSE31595 |
GSE31595 - Gene Expression Profiles in Stage II and III Colon Cancer. Application of a 128-gene signature |
37 |
21703 |
V2 |
| COLON |
GSE16125 |
GSE16125 - Integrative approach for prioritizing cancer genes in sporadic colon cancer |
32 |
14984 |
V2 |
| ESOPHAGUS |
GSE19417 |
GSE19417 - Human esophageal adenocarcinomas |
70 |
17367 |
V2 |
| EYE |
GSE22138 |
GSE22138 - Expression Data from Uveal Melanoma primary tumors. |
63 |
21703 |
V2 |
| EYE |
GSE39717 |
GSE39717 - Gene expression analysis of uveal melanoma tumor tissue |
30 |
21454 |
V2 |
| HEME |
GSE2658 |
GSE2658 - Gene Expression Profiles of Multiple Myeloma |
546 |
21703 |
V2 |
| HEME |
GSE10846 |
GSE10846 - Prediction of survival in diffuse large B cell lymphoma treated with chemotherapy plus Rituximab |
414 |
21703 |
V2 |
| HEME |
GSE16131_U133A |
Differences Between Follicular Lymphoma With and Without Translocation t(14;18) |
180 |
13719 |
V2 |
| HEME |
GSE16131_U133B |
Differences Between Follicular Lymphoma With and Without Translocation t(14;18) |
180 |
10686 |
V2 |
| HEME |
GSE12417_U133A |
GSE12417 - Prognostic gene signature for normal karyotype AML - Affy U133A Samples |
163 |
13480 |
V1 |
| HEME |
GSE12417_U133B |
GSE12417 - Prognostic gene signature for normal karyotype AML - Affy U133B Samples |
162 |
9856 |
V1 |
| HEME |
GSE4475 |
GSE4475 - A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling |
158 |
13719 |
V2 |
| HEME |
TCGA_AML |
TCGA DATA ACUTE MYELOID LEUKEMIA |
157 |
21212 |
V1 |
| HEME |
GSE22762_U133P2 |
An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia |
107 |
21703 |
V2 |
| HEME |
GSE12417_U133P2 |
GSE12417 - Prognostic gene signature for normal karyotype AML - Affy U133plus2 Samples |
79 |
21212 |
V1 |
| HEME |
GSE23501 |
GSE23501 - DNA methylation signatures define molecular subtypes of Diffuse Large B Cell Lymphoma |
69 |
21703 |
V2 |
| HEME |
GSE22762_U133A |
An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia |
44 |
13719 |
V2 |
| HEME |
GSE22762_U133B |
An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia |
44 |
10684 |
V2 |
| HNC |
HNSC_TCGA |
TCGA HEAD AND NECK SQUAMOUS CELL CARCINOMA DATA |
291 |
17187 |
V1 |
| HNC |
E-MTAB-1328 |
E-MTAB-1328 - Methylome, transcriptome and miRNome profiling by array and high throughput sequencing of 89 patients with head and neck squamous cell carcinoma |
60 |
21703 |
V2 |
| HNC |
GSE10300 |
GSE10300 - head and neck squamous cell carcinoma samples |
43 |
21703 |
V2 |
| LIVER |
GSE27150 |
GSE27150 - Transcriptional profile of human liver tissues: hepatocellular carcinoma vs. matched noncancerousliver tissue |
81 |
2456 |
V1 |
| LIVER |
GSE10141 |
GSE10141 - Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma |
80 |
6100 |
V1 |
| LIVER |
GSE17856 |
GSE17856 - Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive HCC |
43 |
14293 |
V2 |
| LUNG |
GSE30219 |
GSE30219 - Off-context gene expression in lung cancer identifies a group of metastatic-prone tumors |
282 |
21703 |
V2 |
| LUNG |
GSE41271 |
GSE41271 - Expression profiling of 275 lung cancer specimens |
275 |
25428 |
V2 |
| LUNG |
GSE31210 |
GSE31210 - Gene expression data for pathological stage I-II lung adenocarcinomas |
226 |
21703 |
V2 |
| LUNG |
GSE50081 |
GSE50081 - Validation of a histology-independent prognostic gene signature for early stage, non-small cell lung cancer including stage IA patients |
181 |
21703 |
V2 |
| LUNG |
GSE42127 |
GSE42127 - Expression data for non-small-cell lung cancer |
176 |
25428 |
V2 |
| LUNG |
TCGA_LUAD |
TCGA DATA LUNG ADEMOCARCINOMA |
150 |
20502 |
V1 |
| LUNG |
GSE8894 |
GSE8894 - Prediction of Recurrence-Free Survival in Postoperative NSCLC Patients - a Useful Prospective Clinical Practice |
138 |
21213 |
V1 |
| LUNG |
GSE4573 |
GSE4573 - Gene expression signatures for predicting prognosis of squamous cell lung carcinomas |
130 |
13480 |
V1 |
| LUNG |
TCGA_LUSC |
TCGA DATA LUNG SQUAMOUS CELL CARCINOMA |
120 |
17813 |
V1 |
| LUNG |
GSE13213 |
GSE13213 - Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis |
117 |
30469 |
V2 |
| LUNG |
GSE26939 |
GSE26939 - Human lung adenocarcinoma mRNA expression and gene mutations |
115 |
17108 |
V1 |
| LUNG |
GSE3141 |
GSE3141 - Lung Cancer Dataset |
111 |
21703 |
V2 |
| LUNG |
GSE37745 |
GSE37745 - Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis and tissue microarray validation |
96 |
21703 |
V2 |
| LUNG |
GSE11969 |
GSE11969 - Expression Profile-Defined Classification of Lung Adenocarcinoma |
90 |
16531 |
V1 |
| LUNG |
GSE14814 |
GSE14814 - Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer |
88 |
13481 |
V1 |
| LUNG |
GSE19188 |
GSE19188 - Expression data for early stage NSCLC |
82 |
21703 |
V2 |
| LUNG |
GSE17710 |
GSE17710 - Human lung squamous cell carcinoma expression profiling |
56 |
17083 |
V2 |
| LUNG |
GSE5843 |
GSE5843 - Expression profiling defines a recurrence signature in lung adenocarcinoma |
48 |
12089 |
V1 |
| LUNG |
GSE11117 |
GSE11117 - Molecular Classification and Prediction of Survival in Non-Small-Cell Lung Cancer |
41 |
9601 |
V1 |
| OVARIAN |
TCGA_OVAD |
TCGA DATA OVARIAN ADENOCARCINOMA |
578 |
12042 |
V1 |
| OVARIAN |
GSE13876 |
GSE13876 - Survival Related Profile, Pathways and Transcription Factors in Ovarian Cancer |
415 |
15971 |
V1 |
| OVARIAN |
GSE9891 |
GSE9891 - Expression profile of 285 ovarian tumour samples |
276 |
21212 |
V1 |
| OVARIAN |
GSE32062 |
GSE32062 - Immune-activation as a therapeutic direction for patients with high-risk ovarian cancer based on gene expression signature |
260 |
19595 |
V1 |
| OVARIAN |
GSE49997 |
GSE49997 - Validating the Impact of a Molecular Subtype in Epithelial Ovarian Cancer (EOC) on Progression Free and Overall Survival |
194 |
16726 |
V2 |
| OVARIAN |
GSE26712 |
GSE26712 - A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer |
185 |
13480 |
V1 |
| OVARIAN |
GSE17260 |
GSE17260 - Prediction of progression-free survival in patients with advanced-stage serous ovarian cancer |
110 |
19566 |
V2 |
| OVARIAN |
GSE14764 |
GSE14764 - A Prognostic Gene Expression Index in Ovarian Cancer |
79 |
13480 |
V1 |
| OVARIAN |
GSE8842 |
GSE8842 - ANALYSIS OF GENE EXPRESSION IN EARLY-STAGE OVARIAN CANCER |
78 |
5631 |
V1 |
| OVARIAN |
GSE30161 |
GSE30161 - Genomic Multivariate Predictors of Response to Adjuvant Chemotherapy in Ovarian Carcinoma: Predicting Platinum Resistance |
58 |
21703 |
V2 |
| OVARIAN |
GSE31245 |
GSE31245 - Unique gene expression profile based upon pathologic response in epithelial ovarian cancer |
55 |
9651 |
V2 |
| OVARIAN |
GSE18520 |
GSE18520 - Whole-genome oligonucleotide expression analysis of papillary serous ovarian adenocarcinomas |
53 |
21703 |
V2 |
| OVARIAN |
GSE32063 |
GSE32063 - Immune-activation as a therapeutic direction for patients with high-risk ovarian cancer based on gene expression signature (2) |
40 |
19566 |
V2 |
| OVARIAN |
GSE19829_U95V2 |
GSE19829 - A gene expression profile of BRCAness that is associated with outcome in ovarian cancer. AffyU95v2 Samples |
39 |
9383 |
V1 |
| OVARIAN |
GSE23554 |
GSE23554 - Ovarian Cancer Dataset |
28 |
13719 |
V2 |
| OVARIAN |
GSE19829_U133P2 |
GSE19829 - A gene expression profile of BRCAness that is associated with outcome in ovarian cancer. AffyU133plus2 Samples |
26 |
21212 |
V1 |
| PANCREAS |
GSE21501 |
GSE21501 - A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma |
102 |
19680 |
V1 |
| PANCREAS |
GSE28735 |
GSE28735 - Microarray gene-expression profiles of 45 matching pairs of pancreatic tumor and adjacent non-tumor tissues from 45 patients with pancreatic ductal adenocarcinoma |
42 |
21096 |
V2 |
| PROSTATE |
GSE16560 |
GSE16560 - Molecular Sampling of Prostate Cancer: a dilemma for predicting disease progression |
281 |
6100 |
V2 |
| PROSTATE |
GSE40272 |
GSE40272 - Gene-expression profiling of prostate tumors |
67 |
9371 |
V1 |
| RECTUM |
TCGA_READ |
TCGA DATA RECTAL ADENOCARCINOMA |
42 |
17728 |
V1 |
| RENAL |
TCGA_KIRC |
TCGA DATA KIDNEY CLEAR CELL CARCINOMA |
528 |
20502 |
V1 |
| RENAL |
GSE29609 |
GSE29609 - Clear-cell renal cell carcinomas tumors |
39 |
18841 |
V1 |
| RENAL |
GSE33371 |
GSE33371 - Beta-catenin status effects in human adrenocortical carcinomas (33), adenomas (22), and normal adrenal cortex (10) |
23 |
21703 |
V2 |
| SKIN |
SKCM_TCGA |
TCGA SKIN CUTANEOUS MELANOMA DATA |
163 |
15341 |
V1 |
| SKIN |
GSE53118 |
GSE53118 - BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma |
79 |
17617 |
V2 |
| SKIN |
GSE22153 |
GSE22153 - Gene Experssion Profiling-Based Identification of Molecular Subtypes in Stage IV Melanoma with Different Clinical Outcome (test set) |
57 |
24614 |
V2 |
| SKIN |
GSE19234 |
GSE19234 - Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. |
44 |
21703 |
V2 |
| STOMACH |
TCGA_STAD |
TCGA DATA STOMACH ADENOCARCINOMA |
18 |
20512 |
V1 |
| UTERUS |
TCGA_UTED |
TCGA DATA UTERINE ENDOMETRIAL CARCINOMA |
54 |
17813 |
V1 |
